Duration of Crohn’s Disease & Response to Vedolizumab (Entyvio)

For patients diagnosed with Crohn’s disease (CD), there seems to be an opportune window in which early intervention may improve outcomes of the disease. Dr. Edward Loftus explains details of a multicenter collaborative  study which found that patients with CD, for 2 years or less,  are more likely to achieve a complete response to vedolizumab (Entyvio), than patients with longer disease duration.

Researchers considered several factors to evaluate the relation between disease duration and vedolizumab effectiveness –

• Clinical remission, defined as absence of symptoms.
• Corticosteroid-free remission (CSFR), defined as tapering off steroids completely, achieving clinical remission, and no repeat steroid prescription within 4 weeks of tapering.
• Endoscopic remission, defined as the absence of ulcers and/or erosions in CD.

What are the implications for patient care?

The findings of the study suggest that patients who’ve been diagnosed with Crohn’s disease should begin treatment with an anti-TNF agent or vedolizumab as soon as possible.

Meet other people, talking about Crohn’s disease, on Mayo Clinic Connect – join the conversation, share experiences, ask questions, and discover your support network. Here are some discussions you might like to follow...

• Crohn’s Disease - Questions about medication
• Systemic IBD, Systemic Anti TNF Therapy
• Crohn’s Disease